Related Experiment Video
Updated: Mar 7, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
"Benzimidazole Derived Non-CDN STING Agonists: Mechanisms, SAR Evolution, and Therapeutic Potential - A Comprehensive
Gajjala Pavani1, Gurubasavaraja Swamy Purawarga Matada1, Abhishek Ghara1
1Integrated Drug Discovery Center, Acharya & B M Reddy College of Pharmacy, Soladevanahalli, Bengaluru 560107, India.
New benzimidazole STING agonists offer improved cancer immunotherapy. These compounds overcome limitations of older drugs, showing potential for more effective and stable treatments against cancer.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- The Stimulator of interferon genes (STING) pathway is crucial for innate immunity and a key target in cancer immunotherapy.
- Traditional STING agonists like cyclic dinucleotides (CDNs) face challenges including poor cell permeability, rapid degradation, and low bioavailability.
- Benzimidazole derivatives are emerging as promising non-CDN STING agonists with enhanced stability and pharmacokinetic properties.
Purpose of the Study:
- To review recent advancements in benzimidazole-based STING agonists for cancer immunotherapy.
- To highlight the structural, functional, and mechanistic properties of these novel compounds.
- To discuss their potential to overcome limitations of existing STING agonists.
Main Methods:
- Review of recent scientific literature on benzimidazole-based STING agonists.
- Analysis of structure-activity relationships (SAR) and mechanisms of action.
- Evaluation of pharmacokinetic properties and therapeutic potential.
Main Results:
- Optimized benzimidazole STING agonists demonstrate enhanced immune response activation and interferon production.
- These novel agonists exhibit improved stability and bioavailability compared to CDNs.
- Structure-activity relationship studies provide insights for further drug design and optimization.
Conclusions:
- Benzimidazole-based STING agonists represent a significant advancement in cancer immunotherapy.
- Their improved properties offer potential for more effective, orally administrable, and long-lasting cancer treatments.
- These novel agents hold promise for improving patient outcomes and expanding therapeutic options in oncology.
More Related Videos
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...